Mylan to Sell Up to $363 Million Biocon Stake in India, Term Sheet Shows

• The sale involves up to 92 million Biocon shares at a total value of 34.81 billion Indian rupees
• The transaction is valued at approximately $363 million based on an exchange rate of 95.62 rupees per dollar
• Details were disclosed in a term sheet reviewed by Reuters, indicating the deal structure is already formalized

Summary: Mylan to Sell Up to $363 Million Biocon Stake in India

Key Transaction Details:

Mylan Inc plans to divest up to 92 million shares of Indian biopharmaceutical company Biocon (BION.NS), valued at approximately 34.81 billion Indian rupees or $363 million, according to a term sheet reviewed by Reuters. The exchange rate cited is $1 = 95.62 Indian rupees.

Companies Involved:

• Mylan Inc: U.S.-based pharmaceutical company executing the share sale
• Biocon: Indian biopharmaceutical firm whose shares are being sold

Market Implications:

This significant stake sale represents a strategic divestment by Mylan in the Indian pharmaceutical sector. The transaction could provide Mylan with substantial liquidity while potentially increasing Biocon's public float. For Biocon, the placement of this block of shares may impact stock liquidity and could attract new institutional investors to the company.

The sale comes as pharmaceutical companies globally reassess their portfolios and strategic holdings. At $363 million, this represents a material transaction in the Indian healthcare sector and could influence Biocon's trading dynamics in the near term.

Context:

The article, published July 13, 2026, provides limited detail beyond the basic transaction parameters, suggesting this information comes from preliminary deal documentation. The timing and pricing mechanism for the stake sale were not disclosed in the available information.

This development warrants monitoring by investors focused on pharmaceutical sector M&A activity, Indian equities, and changes in strategic partnerships within the global biotech industry.